Group B Streptococcus Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses In Vivo

PLoS Pathogens

Volumn 10, Issue 1, 2014, Pages

  Chang, Yung Chi ^a,b   Olson, Joshua ^b   Beasley, Federico C ^b   Tung, Christine ^c   Zhang, Jiquan ^d   Crocker, Paul R ^d   Varki, Ajit ^a,c,e   Nizet, Victor ^a,b,f,g  

^a University of California San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; CYTOKINE; LEUKOCYTE ANTIGEN; N ACETYLNEURAMINIC ACID; SIGLECE PROTEIN, MOUSE;

ANIMAL; BACTERIAL PNEUMONIA; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MOLECULAR MIMICRY; MOUSE; PATHOLOGY; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CYTOKINES; HUMANS; INFLAMMATION; MACROPHAGES; MICE; MICE, KNOCKOUT; MOLECULAR MIMICRY; N-ACETYLNEURAMINIC ACID; PNEUMONIA, BACTERIAL; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 84893722807     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003846     Document Type: Article

References (62)

1. Edwards MS, (2006) Issues of antimicrobial resistance in group B streptococcus in the era of intrapartum antibiotic prophylaxis. Semin Pediatr Infect Dis 17: 149-152.
2. Heath PT, Schuchat A, (2007) Perinatal group B streptococcal disease. Best Pract Res Clin Obstet Gynaecol 21: 411-424.
3. Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, et al. (2011) Bacterial meningitis in the United States, 1998-2007. N Engl J Med 364: 2016-2025.
4. Ferrieri P, Cleary PP, Seeds AE, (1977) Epidemiology of group-B streptococcal carriage in pregnant women and newborn infants. J Med Microbiol 10: 103-114.
5. Galask RP, Varner MW, Petzold CR, Wilbur SL, (1984) Bacterial attachment to the chorioamniotic membranes. Am J Obstet Gynecol 148: 915-928.
6. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, et al. (2008) Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 299: 2056-2065.
7. Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, et al. (2001) Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 323: 533-536.
8. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AK, et al. (2012) Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 379: 547-556.
9. Baltimore RS, (2007) Consequences of prophylaxis for group B streptococcal infections of the neonate. Semin Perinatol 31: 33-38.
10. Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, et al. (2008) Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008: 727505.
11. Schuchat A, (1998) Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 11: 497-513.
12. Edwards MS, Baker CJ, (2005) Group B streptococcal infections in elderly adults. Clin Infect Dis 41: 839-847.
13. Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, et al. (2009) Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 49: 85-92.
14. Rubens CE, Wessels MR, Heggen LM, Kasper DL, (1987) Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A 84: 7208-7212.
15. Wessels MR, Rubens CE, Benedi VJ, Kasper DL, (1989) Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A 86: 8983-8987.
16. Marques MB, Kasper DL, Pangburn MK, Wessels MR, (1992) Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun 60: 3986-3993.
17. Takahashi S, Aoyagi Y, Adderson EE, Okuwaki Y, Bohnsack JF, (1999) Capsular sialic acid limits C5a production on type III group B streptococci. Infect Immun 67: 1866-1870.
18. Crocker PR, Paulson JC, Varki A, (2007) Siglecs and their roles in the immune system. Nat Rev Immunol 7: 255-266.
19. Varki A, (2007) Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 446: 1023-1029.
20. Cao H, Crocker PR, (2011) Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology 132: 18-26.
21. Pillai S, Netravali IA, Cariappa A, Mattoo H, (2012) Siglecs and immune regulation. Annu Rev Immunol 30: 357-392.
22. Varki A, Angata T, (2006) Siglecs-the major subfamily of I-type lectins. Glycobiology 16: 1R-27R.
23. Paul SP, Taylor LS, Stansbury EK, McVicar DW, (2000) Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 96: 483-490.
24. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML, (1999) The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol 29: 3440-3449.
25. Ulyanova T, Shah DD, Thomas ML, (2001) Molecular cloning of MIS, a myeloid inhibitory siglec, that binds protein-tyrosine phosphatases SHP-1 and SHP-2. J Biol Chem 276: 14451-14458.
26. Varki A, (2011) Since there are PAMPs and DAMPs, there must be SAMPs? Glycan "self-associated molecular patterns" dampen innate immunity, but pathogens can mimic them. Glycobiology 21: 1121-1124.
27. Carlin AF, Lewis AL, Varki A, Nizet V, (2007) Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes. J Bacteriol 189: 1231-1237.
28. Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, et al. (2009) Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113: 3333-3336.
29. Zhang JQ, Biedermann B, Nitschke L, Crocker PR, (2004) The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 34: 1175-1184.
30. Boyd CR, Orr SJ, Spence S, Burrows JF, Elliott J, et al. (2009) Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production. J Immunol 183: 7703-7709.
31. McMillan SJ, Sharma RS, McKenzie EJ, Richards HE, Zhang J, et al. (2013) Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b beta2-integrin-dependent signalling. Blood 121: 2084-2094.
32. Redelinghuys P, Antonopoulos A, Liu Y, Campanero-Rhodes MA, McKenzie E, et al. (2011) Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E. J Biol Chem 286: 34522-34532.
33. Gergely J, Pecht I, Sarmay G, (1999) Immunoreceptor tyrosine-based inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-based activation motif-induced activation of immune competent cells. Immunol Lett 68: 3-15.
34. Zhang J, Somani AK, Siminovitch KA, (2000) Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol 12: 361-378.
35. Taylor LS, Paul SP, McVicar DW, (2000) Paired inhibitory and activating receptor signals. Rev Immunogenet 2: 204-219.
36. Chang YC, Uchiyama S, Varki A, Nizet V, (2012) Leukocyte inflammatory responses provoked by pneumococcal sialidase. MBio 3: e00220-11.
37. Ando M, Tu W, Nishijima K, Iijima S, (2008) Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem Biophys Res Commun 369: 878-883.
38. Chen GY, Chen X, King S, Cavassani KA, Cheng J, et al. (2011) Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol 29: 428-435.
39. Shigeoka AO, Rote NS, Santos JI, Hill HR, (1983) Assessment of the virulence factors of group B streptococci: correlation with sialic acid content. The Journal of infectious diseases 147: 857-863.
40. Wessels MR, Haft RF, Heggen LM, Rubens CE, (1992) Identification of a genetic locus essential for capsule sialylation in type III group B streptococci. Infection and immunity 60: 392-400.
41. Rivest S, (2009) Regulation of innate immune responses in the brain. Nat Rev Immunol 9: 429-439.
42. Mariani MM, Kielian T, (2009) Microglia in infectious diseases of the central nervous system. J Neuroimmune Pharmacol 4: 448-461.
43. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ, (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13-25.
44. Gupta N, Scharenberg AM, Burshtyn DN, Wagtmann N, Lioubin MN, et al. (1997) Negative signaling pathways of the killer cell inhibitory receptor and Fc gamma RIIb1 require distinct phosphatases. J Exp Med 186: 473-478.
45. Maeda A, Kurosaki M, Ono M, Takai T, Kurosaki T, (1998) Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J Exp Med 187: 1355-1360.
46. Ono M, Bolland S, Tempst P, Ravetch JV, (1996) Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 383: 263-266.
47. Lajaunias F, Dayer JM, Chizzolini C, (2005) Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol 35: 243-251.
48. Ohta M, Ishida A, Toda M, Akita K, Inoue M, et al. (2010) Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9. Biochem Biophys Res Commun 402: 663-669.
49. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, et al. (1999) Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 189: 179-185.
50. Nadler MJ, McLean PA, Neel BG, Wortis HH, (1997) B cell antigen receptor-evoked calcium influx is enhanced in CD22-deficient B cell lines. J Immunol 159: 4233-4243.
51. O'Keefe TL, Williams GT, Davies SL, Neuberger MS, (1996) Hyperresponsive B cells in CD22-deficient mice. Science 274: 798-801.
52. Yuasa T, Kubo S, Yoshino T, Ujike A, Matsumura K, et al. (1999) Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med 189: 187-194.
53. Zhang M, Angata T, Cho JY, Miller M, Broide DH, et al. (2007) Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109: 4280-4287.
54. Crocker PR, McMillan SJ, Richards HE, (2012) CD33-related siglecs as potential modulators of inflammatory responses. Ann N Y Acad Sci 1253: 102-111.
55. Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, et al. (2001) Interleukin-10 in the brain. Crit Rev Immunol 21: 427-449.
56. Malipiero U, Koedel U, Pfister HW, Leveen P, Burki K, et al. (2006) TGFbeta receptor II gene deletion in leucocytes prevents cerebral vasculitis in bacterial meningitis. Brain 129: 2404-2415.
57. Banerjee S, Bhat MA, (2007) Neuron-glial interactions in blood-brain barrier formation. Annu Rev Neurosci 30: 235-258.
58. Wang Y, Neumann H, (2010) Alleviation of neurotoxicity by microglial human Siglec-11. J Neurosci 30: 3482-3488.
59. Lewis AL, Nizet V, Varki A, (2004) Discovery and characterization of sialic acid O-acetylation in group B Streptococcus. Proc Natl Acad Sci USA 101: 11123-11128.
60. Angata T, Varki A, (2000) Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways. J Biol Chem 275: 22127-22135.
61. Moussaud S, Draheim HJ, (2010) A new method to isolate microglia from adult mice and culture them for an extended period of time. J Neurosci Methods 187: 243-253.
62. Doran KS, Engelson EJ, Khosravi A, Maisey HC, Fedtke I, et al. (2005) Blood-brain barrier invasion by group B Streptococcus depends upon proper cell-surface anchoring of lipoteichoic acid. J Clin Invest 115: 2499-2507.